Relypsa Begins Treatment In AMETHYST-DN Trial Of RLY5016 For Hyperkalemia In Diabetic Nephropathy Patients With Chronic Kidney Disease

Links shared publicly online about this topic.

  • 183
    total visits

Relypsa Begins Treatment In AMETHYST-DN Trial Of RLY5016 For Hyperkalemia In Diabetic Nephropathy Patients With Chronic Kidney Disease

medicalnewstoday.com —

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD).

View full resource at medicalnewstoday.com

Tags: Diabetes, Kidney Health, Urinary System, Kidney Disease, End-Stage Renal Disease, Chronic Kidney Disease, Nephropathy

  • Share

Most Recently Shared on June 29, 2011 at 6:05 pm By:

mnt_diabetes MNT Diabetes News

Relypsa Begins Treatment In AMETHYST-DN Trial Of RLY5016 For Hyperkalemia In Diabetic Nephropathy Patients With Chroni... http://mnt.to/3XNp

10 months ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Urology MNT Urology

Advertisement